Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of ADMA's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Jul 16, 2025
Questions asked 63 each answered in the company's own letter
No closing letter 3 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 11 UPLOAD
  2. 2. Questions in them 63 numbered comments
  3. 3. Company replies 22 CORRESP
  4. 4. Reviews closed 2 of 5 closing letter

Half the closed reviews took 122 days or less from the first letter to the closing letter.

Form 10-K for the fiscal year ended December 31, 2024

2025-07-16 to 2025-09-29 · 3 questions · 3 letters from the SEC, 3 from the company
Review closed 2025-09-29
RevenueSegmentsResults discussion (MD&A)Income taxesInventory
SEC asked
We note your analysis of revenues for the periods presented on pages 73 and 75, including the 65% increase in revenue in 2024 and improved operating results which contributed to net income on a GAAP basis for the first time, and your expectation of increased physician, payer and patient acceptance and utilization of ASCENIV, as well as sales increases for some of your other IG products.
Rest of the question

Please address the following: • Please revise your future filings to provide a breakout of revenue by product. Refer to Item 303(b)(2)(ii) of Regulation S-K and ASC 280-10-50-40. In light of the Voluntary Withdrawal in the first quarter of 2025, please revise your future filings to disclose your methodology for how you account for product returns and how the Voluntary Withdrawal had an impact on your ability to make • 1. estimates of variable consideration vis a vis the gradual increase in charges to the inventory valuation allowance over the last three years as shown in your Schedule II. • Consider providing a tabular rollforward of significant adjustments to revenue such as product returns for the periods presented.

ADMA answered
The Company acknowledges the Staff’s comment. ASC 280-10-50-40 requires a public entity to “report the revenues from external customers for each product and service or each group of similar products and services unless it is impracticable to do so.”

The Company has analyzed its products and services under both Item 303(b)(2)(ii) of Regulation S-K and ASC 280-10-50-40, and determined that its products should be grouped as follows:

◾

Immune Globulin (IG) Products: Consists of revenue from sales of ASCENIV, BIVIGAM and Nabi-HB, all FDA-approved for treatment of Primary Immunodeficiency,
Rest of the answer

manufactured in the same manner, all utilizing human source plasma as the starting raw material and distributed to similar customers through a shared sales infrastructure.

Plasma, Intermediates and Other: Consists of the following: (i) sales of human source plasma to third parties, (ii) sales of intermediates, which consist of sales of partially processed biologics, not intended for final therapeutic use and sold to third-party manufacturers or testing organizations, rather than to end users as a therapeutic, and (iii) other miscellaneous revenue.

For the years ended December 31, 2024, 2023 and 2022, IG Products represented 94%, 92% and 89%, respectively, of our total revenue.

Accordingly, in future filings, the Company will provide a narrative breakout of revenue, per the above proposed product groups, within the Management’s

Discussion and Analysis of Financial Condition and Results of Operations to address the requirements of Item 303(b)(2)(ii) of Regulation S-K.

In light of the Voluntary Withdrawal in the first quarter of 2025, please revise your future filings to disclose your methodology for how you account for product returns and how the Voluntary

Withdrawal had an impact on your ability to make estimates of variable consideration vis a vis the gradual increase in charges to the inventory valuation allowance over the last three years as shown in your Schedule II.

Response: The Company acknowledges the Staff’s comment and respectfully advises the Staff that the change to the

Company’s inventory valuation allowance over the last three years as shown in Schedule II is attributed to normal manufacturing activities, mainly related to the Company’s expiring materials. The Company’s recorded inventory return charges over the last three years were less than $0.5 million in the aggregate. Therefore, the charges to the inventory valuation allowance over the last three years were not related to product returns.

Accordingly, the Company evaluates the need for inventory valuation allowance with consideration of its experience with product returns, and believes its disclosures are appropriate based on the historically infrequent and immaterial nature of the same.

During the first quarter of 2025, we voluntarily withdrew certain products. We have not had instances of any withdrawals, voluntary or otherwise, prior to 2025.

While it is possible we may have a product withdrawal in the future, any such withdrawal is unlikely and not expected to be common or recurring in nature. Therefore, based on our historical experience as well as our expectation, no material reserves for product withdrawals (whether voluntary or involuntary) are necessary. We will continue monitoring and consider establishing an allowance for product withdrawals, should we experience any withdrawals in the future.

Consider providing a tabular rollforward of significant adjustments to revenue such as product returns for the periods presented.

Response: The Company acknowledges the Staff’s comment and respectfully advises that Staff that significant adjustments to revenue are infrequent, and historically, the Company provided detailed narrative disclosures in its Management’s Discussion and Analysis of Financial Condition and Results of Operations regarding nature, timing and impact with respect to such adjustments, if deemed material. The Company will continue to monitor the frequency, materiality and nature of such adjustments going forward and will consider providing a tabular roll forward to the extent such a presentation would provide additional clarity and insight.

The Company thanks the Staff for its review of the foregoing. If you have any questions or comments, please feel free to contact our counsel, David C. Schwartz, Esq. at [email protected] or by telephone at

(609) 919-6680.

Read in the reply
SEC asked
Management's Discussion and Analysis of Financial Condition and Results of Operations, Results of Operations, page 70 Please address the following regarding your response to comment one. From your recent earnings calls, it appears there has been a shift in the mix of your three Immune Globulin (IG) products over the last eight quarters.
Rest of the question

During these investor calls, you have been able to provide quantification of the shift between these respective IG products, the shift of which appears to be of significant interest to the investing community, especially leading up to and since the yield enhancement. As you noted in your response, for the years ended December 31, 2024, 2023 and 2022, the three IG Products represented 94%, 92% and 89%, respectively, of your total revenue. Accordingly, a breakout that presents all three IG products as a single unit, may not be 1. as informative as one that separately quantifies each of them. • Tell us how you specifically considered the guidance in Item 303(b)(2)(i) and (ii) of Regulation S-K in your analysis, since your IG products as a whole constitute substantially all of your revenue and there may be sales trends for each IG product within that group that warrant disclosure as seem to be referenced in your earnings calls. • Further, in applying the guidance of ASC 280-10-50-40, an enterprise with a relatively narrow product line may not consider two products to be similar, while an enterprise with a broad product line may consider those same two products to be similar. Please amplify your discussion of your application of ASC 280-10-5040 to explain how you considered whether the concentration of substantially all your revenues being from only three IG products would warrant further disaggregation. • As part of your response, please provide us with a sample breakdown of revenue from the three IG products for recent periods.

ADMA answered
The Company respectfully acknowledges the Staff’s comment. The Company has reviewed Item 303(b)(2)(i) and (ii) of Regulation S-K and ASC 280-10-50-40. The Company advises the Staff that it considers and follows the provisions of ASC 280-10-50-40, “Information about Products and Services” (“ASC 280-10-50-40”), when preparing its financial statements. ASC 280-10-50-40 states that a public entity shall report the revenues from external customers for each product and service or each group of similar products and services unless it is impracticable to do so.
Rest of the answer

The Company discloses revenues from its ADMA

BioManufacturing operating segment, whose business activities consist of the manufacturing and sales of the Company’s Immune Globulin (IG) products. The Company respectfully submits that the products and services produced and sold by this operating segment, including the products noted in the Staff’s comment, in all material respects constitute groups of similar products, and that further disaggregation of revenues within these groups is therefore not required by ASC 280-10-50-40.

The Company appreciates the Staff’s noting recent discussion among investors on the Company’s earnings calls, including investment community interest in various trends in our product revenues. In considering the Staff’s comments, the Company has determined that providing further dissection of our revenues amongst the similar IG products within the BioManufacturing operating segment would be competitively harmful to the Company.

The Company believes that disclosing a detailed breakdown of revenue by product would be competitively harmful for several reasons. The Company anticipates that its competitors would use this information to strategically and actively target the relatively small pool of patients who benefit from particular IG products in the Company’s portfolio and seek to usurp market share of those products. In addition, the Company’s competitors or those seeking to research and develop new or competing products may use such disaggregated revenue details to develop their own product pipelines, based on perceived demand or supply for such particular products.

Additionally, disclosing such information could potentially weaken our ability to negotiate commercial arrangements with external third parties, such as suppliers or vendors, as such third parties could leverage this sensitive information to our disadvantage, which could impact our ability to secure agreements on optimal terms and even make certain proposed arrangements commercially prohibitive to the Company. Any of the foregoing scenarios could adversely affect the Company’s market share, which in turn, would negatively harm the Company’s stockholders. Furthermore, the Company has reviewed SEC filings by certain of the Company’s competitors, including certain of the listed foreign competitors as discussed within our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, under “Item 1. Business—Competition”, and has noted that these competitors do not appear to be disclosing disaggregated revenue of their respective immune globulin products in their public filings. As a result, if the Company were required to disclose such detailed, disaggregated revenue of each of its IG products within a single operating segment, such disclosure would put the Company at a significant competitive disadvantage given the imbalance of information among competitors.

The Company believes that it must remain mindful that the requested disclosure could potentially affect its competitive position. Accordingly, the Company respectfully prefers to continue reporting its financials in the manner it has historically, which the Company believes provides transparency while preserving important competitive considerations.

Notwithstanding the foregoing, the Company remains committed to working collaboratively with the Staff and would welcome the opportunity to further discuss these considerations.

Should the Staff ultimately take a different view, the Company proposes the following approach to address the Staff’s comments constructively.

Albeit competitively harmful, if the Staff determines such an approach is necessary, then beginning with the Company’s Annual Report on Form 10-K for the year ending December 31, 2025

(the “2025 Form 10-K”), and continuing in Quarterly Reports on Form 10-Q beginning thereafter, the Company will expand its discussion of revenue performance by respective products in the notes to the financial statements and in the Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) section of the Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, to include a tabular breakdown of revenue, and the Company will also disclose product margins on a blended basis, as shown below. Solely as an example, the Company presents on Exhibit A attached hereto a sample of how such disclosure would appear for the years ended December 31, 2025 and 2024, respectively.

Please note the Company’s proposed discussion of revenue performance by its respective products in MD&A of its 2025 Form 10-K:

Revenues

We recorded total revenues of $XXX million for the year ended December 31, 2025, as compared to $426.5 million for the year ended December 31, 2024, an

[increase/decrease] of $XXX million, or XX%. This [increase/decrease] is primarily related to [increased/decreased] sales of ASCENIV and BIVIGAM, which collectively represented XX% of our total IG product portfolio sales in the current period, as we continue to experience [increased/decreased] physician, payer and patient acceptance and utilization and [increased/decreased] volume of sales of these products. In addition, we experienced [higher/lower] sales of our other IG products and [an increase / a decrease] in sales of normal source plasma (“NSP”) and hyperimmune Hepatitis B plasma by our Plasma Collection Centers business segment in the amount of $XX million.

Further, in applying the guidance of ASC 280-10-50-40, an enterprise with a relatively narrow product line may not consider two products to be similar, while an enterprise with a broad product line may consider those same two products to be similar. Please amplify your discussion of your application of ASC ###-##-#### to explain how you considered whether the concentration of substantially all your revenues being from only three IG products would warrant further disaggregation.

Response: The Company respectfully acknowledges the Staff’s comment. The Company has reviewed ASC 280-10-50-40 and, as noted above, if the Staff so requires, would plan to revise and update its discussion of revenue performance by its respective products in the notes to the financial statements and in the MD&A section of the 2025 Form 10-K.

As part of your response, please provide us with a sample breakdown of revenue from the three IG products for recent periods.

Response: The Company respectfully acknowledges the Staff’s comment and, as described above, if the Staff so requires, proposes to present a breakdown of revenue from its IG products as illustrated on Exhibit A attached hereto.

In response to the Staff’s verbal comment regarding the Company’s voluntary withdrawal during the three months ended March 31, 2025, the Company provided additional disclosure and information in the MD&A section in its Form 10-Q for the three months ended June 30, 2025 filed with the Commission on August 6, 2025 (“Q2 2025 Form 10-Q”). The Company also updated disclosure in a related risk factor to address this matter in the Q2 2025 Form 10-Q. The additional disclosure in the MD&A is referenced below, for the Staff’s convenience:

Q2 2025 Form 10-Q, page 26

“During the three months ended June 30, 2025, and as previously disclosed in our Form 10-Q for the three months ended March 31, 2025, that was filed with the Securities and

Exchange Commission (the “SEC”) on May 7, 2025 (the "2025 1Q 10-Q"), we voluntarily withdrew three lots of BIVIGAM (such a withdrawal, hereinafter referred to as the “Voluntary Withdrawal”) as a precautionary measure. This resulted in a reduction in revenue of $0.2 million for credits issued to customers that were impacted by this Voluntary Withdrawal during the current period. This action was proactively initiated, and we believe this matter to be resolved.”

Q2 2025 Form 10-Q, page 28

“During the six months ended June 30, 2025, and as previously disclosed in the 2025 1Q 10-Q, we effected the Voluntary Withdrawal as a precautionary measure. This resulted in a reduction in revenue of $4.0 million for credits issued to customers that were impacted by this Voluntary Withdrawal during the current period. This action was proactively initiated, and we believe this matter to be resolved.”

The Company thanks the Staff for its review of the foregoing. If you have any questions or comments, please feel free to contact our counsel, David C. Schwartz, Esq. at [email protected] or by telephone at

(609) 919-6680.

Read in the reply
SEC asked
We appreciate your response to prior comment one, including your concerns about the possibility that the proposed disclosure could be competitively harmful. However, we continue to believe such disclosure is required and would be useful to investors. Please revise your future filings accordingly.
ADMA answered
The Company respectfully acknowledges the Staff’s comment and will revise future filings accordingly. Commencing with the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025, and continuing in Quarterly Reports on Form 10-Q beginning thereafter, the Company will expand its discussion of revenue performance by respective Immune Globulin products in the notes to the financial statements and in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of its Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q, as
Rest of the answer

applicable, to include a tabular breakdown of revenue, and the Company will also disclose product revenue on a blended basis, substantially in the respective example forms presented in the Company’s August 13, 2025 Response Letter.

Securities and Exchange Commission

September 22, 2025

The Company thanks the Staff for its review of the foregoing. If you have any questions or comments, please feel free to contact our counsel, David C. Schwartz, Esq. at [email protected] or by telephone at (609) 919-6680.

Read in the reply

Also in this review: closing letter, 2025-09-29

Form S-1

2017-10-18 to 2017-11-06 · 1 question · 1 letter from the SEC, 3 from the company
No closing letter
Registration Statement on Form S-1 filed October 11, 2017 · Underwriting, page 81
SEC asked
Based on your disclosure on the cover page and in this section, it appears you are registering a firm commitment underwritten offering of your common stock at a fixed price on a non-delayed and non-continuous basis. Given this, please explain your disclosure, "After the initial offering of the shares of Common Stock, the offering price and other selling terms may be changed by the underwriters."
ADMA answered
The Company acknowledges the Staff’s comment and has revised page 81 of Amendment No. 1 to clarify the terms of the Company’s proposed fixed price, non-delayed, non-continuous offering.

The Company appreciates the Staff's attention to the review of the Registration Statement. Please contact the undersigned at (973) 520-2555 if you have any questions regarding the foregoing.
Read in the reply

Also in this review: company letter, Nov 6, 2017, company letter, Nov 6, 2017

Form S-1

2013-02-12 to 2013-05-01 · 1 question · 1 letter from the SEC, 6 from the company
No closing letter
SEC asked
Please file the legal opinion of SNR Denton as exhibit 5.1 to your registration statement. We may have further comments based on our review of the opinion.
ADMA answered
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the Company hereby requests that the effectiveness of the above-captioned Registration Statement be accelerated to 4:00 pm Eastern Time on April 24, 2013, or as soon thereafter as is practicable.

In connection with this letter, the Company acknowledges that:

· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

·
Rest of the answer

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: company letter, Apr 23, 2013, company letter, Apr 25, 2013, company letter, Apr 30, 2013, company letter, Apr 30, 2013, company letter, May 1, 2013

Form S-1

2012-04-24 to 2012-07-03 · 14 questions · 3 letters from the SEC, 3 from the company
No closing letter
Critical estimatesResults discussion (MD&A)Risk factors
General
SEC asked (1)
Since you appear to qualify as an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (“the Act”), please disclose on your prospectus cover page that you are an emerging growth company, and revise your prospectus to provide the following additional disclosures:  Describe how and when a company may lose emerging growth company status;  A brief description of the various exemptions that
Rest of the question

are available to you, such as exemptions from Section 404(b) of the Sarbanes-Oxley Act of 2002 and Section 14A(a) and (b) of the Securities Exchange Act of 1934; and  Your election under Section 107(b) of the Act: o If you have elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the Act, include a statement that the election is irrevocable; or o If you have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2)(B) of the Act, provide a risk factor explaining that this election allows you to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Please state in your risk factor that, as a result of this election, your financial statements may not be comparable to companies that comply with public company effective dates. Include a similar statement in your critical accounting policy disclosures in MD&A.

ADMA answered
The Company has added the requested disclosure to the prospectus cover page, as well as to pages 4, 32 and 61 of the Amendment.
Read in the reply
General
SEC asked (2)
We note the comment letters from the staff dated March 9, 2012 and April 12, 2012 regarding your Form 8-K filed on February 13, 2012, as amended. Please be advised that your outstanding comments concerning the Form 8-K must be resolved prior to the effectiveness of this Form S-1 registration statement.
Rest of the question

Additionally, to the extent you amend the Form 8-K, in response to comments or otherwise, please revise to make any applicable conforming changes to this Form S-1.

ADMA answered
The Company acknowledges the Staff’s comments and will, to the extent it amends the Form 8-K, revise the registration statement on Form S-1 to make any applicable conforming changes. It has also revised the registration statement on Form S-1 to include applicable changes made in Amendment No. 2 to Form 8-K filed on April 24, 2012.
Read in the reply
General
SEC asked (3)
We note your pending confidential treatment request related to Exhibits 10.8 and 10.9 incorporated by reference to your Form 8-K filed on February 13, 2012. Please note that the staff must act on this confidential treatment request before the acceleration of effectiveness of this Form S-1.
ADMA answered
The Company acknowledges the Staff’s comment.
Read in the reply
General
SEC asked (4)
It appears that the offering by the selling stockholders may be an indirect primary offering rather than a secondary offering. Please revise to name each of the selling stockholders as underwriters and to conduct the offering at a fixed price or provide detailed legal analyses explaining why this is not necessary.
ADMA answered
Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), provides that “(a) Securities may be registered for an offering to be made on a continuous or delayed basis in the future, provided, that: (1) The registration statement pertains only to: (i) Securities which are to be offered or sold solely by or on behalf of a person or persons other than the registrant, a subsidiary of the registrant, or a person of which the registrant is a subsidiary….”

In the event that an offering registered in reliance on Rule 415(a)(1)(i) is deemed to be an offering that is “by
Rest of the answer

or on behalf of the registrant” as specified in Rule 415(a)(1)(x), Rule 415 contains additional limitations. Rule 415(a)(4) provides that:

“In the case of a registration statement pertaining to an at the market offering of equity securities by or on behalf of the registrant, the offering must come within paragraph (a)(1)(x) of this section. As used in this paragraph, the term ‘at the market offering’ means an offering of equity securities into an existing trading market for outstanding shares of the same class at other than a fixed price.”

As a result, if an offering which purports to be a secondary offering is recharacterized as an offering “by or on behalf of the registrant,” Rule 415 is only available to register an “at the market offering” if the registrant is eligible to use Form S-3 or Form F-3 to register a primary offering. The Company is currently not eligible to use Form S-3 to effect a primary offering. Therefore, it cannot use Rule 415 to register a primary offering “at the market.”

In the event that the offering covered by the registration statement is recharacterized as a primary offering on behalf of the Company, (i) the offering would have to be made on a fixed price basis (in other words, the selling stockholders would not be able to sell their securities at prevailing market prices), (ii) the selling stockholders would be deemed to be “underwriters” (with the attendant liabilities under Section 11 of the Securities Act) and (iii) in accordance with the Staff’s long-standing interpretive position, Rule 144 would never be available to them to effect resales of their securities.

Because of the requirements of Rule 415, the Staff’s interpretation that the resale of the securities covered by the registration statement (the “Registrable Shares”) appears to be a primary offering would have a dramatic impact on the ability of a selling stockholder to effect the resale of its shares. Because such a recharacterization would have such a dramatic impact, and a mischaracterization could have a chilling effect on the ability of smaller public companies, like the Company, to raise capital, the Staff should only recharacterize a secondary offering as being made on behalf of a registrant after careful and complete review of the relevant facts and circumstances.

In Compliance and Disclosure Interpretation 612.09 (“CDI 612.09”) with respect to the rules under the Securities Act, the Staff acknowledged that:

[i]t is important to identify whether a purported secondary offering is really a primary offering, i.e., the selling shareholders are actually underwriters selling on behalf of an issuer. Underwriter status may involve additional disclosure, including an acknowledgment of the seller’s prospectus delivery requirements. In an offering involving Rule 415 or Form S-3, if the offering is deemed to be on behalf of the issuer, the Rule and Form in some cases will be unavailable (e.g., because of the Form S-3 “public float” test for a primary offering, or because Rule 415(a)(1)(i) is available for secondary offerings, but primary offerings must meet the requirements of one of the other subsections of Rule 415). The question of whether an offering styled a secondary one is really on behalf of the issuer is a difficult factual one, not merely a question of who receives the proceeds. Consideration should be given to how long the selling shareholders have held the shares, the circumstances under which they received them, their relationship to the issuer, the amount of shares involved, whether the sellers are in the business of underwriting securities, and finally, whether under all the circumstances it appears that the seller is acting as a conduit for the issuer. (emphasis added)

After consideration of all of the factors listed in CDI 612.09, which are discussed in detail below in the context of the registration statement, it is the Company’s view that the offering of the Registrable Shares is a valid secondary offering and is eligible to be made under Rule 415(a)(1)(i) under the Securities Act as contemplated by the registration statement.

The date on which and the circumstances in which each selling stockholder received the shares and/or the overlying securities

1,828,128 of the 1,969,026 Registrable Shares were acquired by selling stockholders in the reverse merger in exchange for shares received in the 2012 Financing effected in connection with such reverse merger on February 13, 2012. 53,044 of the Registrable Shares were acquired by selling stockholders in exchange for shares received in connection with the organization of ParentCo in 2006. Furthermore, 87,865 of the Registrable Shares are issuable upon exercise of warrants acquired by the placement agent in exchange for warrants issued to the placement agent in the 2012 Financing.

In any event, however, the length of time for which the selling stockholders will have held their Registrable Shares or overlying securities prior to resale pursuant to the registration statement is only one factor cited in CDI 612.09, to be considered alongside the other factors listed therein in arriving at a conclusion, after careful and complete review of the relevant facts and circumstances, of whether the transaction at issue is in fact a primary offering.

Also relevant to the analysis are the circumstances under which the selling stockholders received the Registrable Shares and/or the overlying securities. In the case at hand, the selling stockholders received the Registrable Securities and/or the overlying securities in the reverse merger in exchange for securities received either in the 2012 Financing or at the organization of ParentCo. In both cases, the issuances were valid private placements under Section 4(2) of the Securities Act and Regulation D promulgated thereunder.

All of the selling stockholders acquired their Registrable Shares, or in the case of the Placement Agent Warrants, such warrants, for investment and specifically represented to the Company that they were not acquiring their securities with a view to distribution or resale of the securities except in full compliance with all applicable provisions of the Securities Act. There is no evidence to suggest that those representations are false. The mere fact that the Registrable Shares are now being registered for resale is no evidence that the selling stockholders desire to effect an immediate distribution. In fact, there are a number of reasons why investors want shares registered other than to effect an immediate sale. Many private investment funds, for example, some of which are among the selling stockholders, are required to mark their portfolios to market. If portfolio securities are not registered, such investors are required to mark down the book value of those securities to reflect an illiquidity discount. That portfolio valuation does not depend on whether the selling stockholders intend to dispose of their shares or to hold them for an indefinite period. In addition, many investors are fiduciaries of other people’s money and have a common law duty to act prudently. It would be irresponsible for those investors not to have their shares registered. Not registering the shares would prevent them from taking advantage of market opportunities or from liquidating their investment if there is a fundamental shift in their investment judgment about the Company. Finally, registered shares of many issuers are eligible to be used as margin collateral under the Federal Reserve’s margin regulations. Restricted securities cannot be “margin stock.” The potential diminution of value of holding unregistered securities relative to holding registered securities explains why the selling stockholders negotiated for registration rights during the negotiations that preceded the 2012 Financing.

There is also no evidence that the selling stockholders are acting in concert to effect a distribution of the Registrable Shares. There are 16 persons or entities for whom the sale of securities is being registered in the registration statement. There is no evidence that the selling stockholders have any plan to act in concert with respect to their Registrable Shares. Under the Exchange Act of 1934, as amended (the “Exchange Act”), such a plan would make such investors a “group” under Section 13(d) of the Exchange Act. In similar circumstances, courts have found that investors who merely sign the same investment documents do not constitute a “group” for 13(d) purposes. See, e.g., Litzler v. CC Investments, 411 F.Supp. 2d 411 (S.D.N.Y. 2006) (investors participating in the same financing and signing the same investment documents prepared by one counsel are not a “group”). Accordingly, there does not appear to be any valid basis to impute to the selling stockholders any intent to act in concert.

Furthermore, under the Commission’s own rules, a “distribution” requires special selling efforts. Rule 100(b) of Regulation M defines a “distribution” as

“an offering of securities, whether or not subject to registration under the Securities Act, that is distinguished from ordinary trading transactions by the magnitude of the offering and the presence of special selling efforts and selling methods.” (Emphasis added)

There is no evidence in this case that any special selling efforts or selling methods have taken place or would take place if the sale of all of the Registrable Shares were registered. Again, it is unlikely that the selling stockholders in the 2012 Financing will band together to distribute their shares. Nor is there any evidence that any of the selling stockholders have conducted any road shows or taken any other actions to condition or “prime” the market for their shares. To do so would violate the detailed representations made by them in documents executed in connection with the 2012 Financing and the reverse merger.

Further reducing the probability of a distribution intent is the fact that approximately 74% of the Registrable Shares were issued to parties who are now affiliates of the Company (“Affiliates”) although certain of such parties were not Affiliates prior to the 2012 Financing. Under Section 16(b) under the Exchange Act and Rule 16b-6 thereunder, Affiliates would be subject to short-swing profit liability if they sold any of the Registrable Shares within six months of the 2012 Financing.

Finally, for practical purposes, it would be extremely difficult for the selling stockholders to distribute the Registrable Shares in the near future. The Company’s common stock is not listed or quoted on any stock exchange or stock quotation service. Even at such time as the Company has qualified its common stock for quotation on the Over-the-Counter Bulletin Board, it cannot provide assurances that there will be any active trading market for its common stock, a risk that is disclosed on the prospectus cover and elsewhere in the registration statement. It would appear that an investor purchasing shares could not have a reasonable expectation that they could effect an immediate distribution for common stock that does not have an active trading market. In this situation -- as is the case with many PIPE transactions -- the concept that the selling stockholders have “freely tradable” shares is far more theoretical than real. For practical purposes, the selling stockholders would have difficulty liquidating their investments, regardless of whether their shares are registered.

The relationship of each selling stockholder with the Company

Affiliates

Of the 1,969,026 Registrable Shares (including 87,865 Registrable Shares issuable upon the exercise of the Placement Agent Warrant), only 572,918 Registrable Shares (representing approximately 29% of the Registrable Shares) are held by persons who were Affiliates of the Company prior to the time of their investment, counting each of (i) the Grossman Group and (ii) Aisling and its control person Steven Elms as one Affiliate. Aisling and the Grossman Group were already securityholders in Former ADMA prior to the 2012 Financing and neither of them have, to the Company’s knowledge, ever sold shares of the Company or Former ADMA. This provides support for the Company’s argument that such Affiliates have acquired their securities for investment and not with the intent to effect a distribution of the Registrable Shares.

Of the 1,969,026 Registrable Shares (including 87,865 Registrable Shares issuable upon the exercise of the Placement Agent Warrant), 885,417 Registrable Shares (representing approximately 45%) are held by Burrill. Burrill did not hold securities of the Company or Former ADMA prior to the 2012 Financing, and therefore only became an Affiliate as a result of the 2012 Financing.

Non-Affiliates

Of the 1,969,026 Registrable Shares (including 87,865 Registrable Shares issuable upon the exercise of the Placement Agent Warrant), 510,691 Registrable Shares (representing approximately 26% of the Registrable Shares), are held by eight non-affiliates (“Non-Affiliates”).

Of the Non-Affiliates, three were already securityholders in ParentCo, or affiliated with securityholders of ParentCo, and have been investors in the Company’s predecessor for at least the past five years.

Whether or not any of the selling stockholders is in the business of buying and selling securities

The selling stockholders are individuals and private investment funds that buy and sell portfolio securities for their own accounts and performed significant, fundamental due diligence on the Company prior to making their investment. All of the selling stockholders represented at the time of purchase of the Registrable Shares that they were buying for their own accounts, for investment and not with a view to distribution or resale of securities except in full compliance with all applicable provisions of the Securities Act. There is no allegation that those representations and warranties are untrue and no factual basis for any such allegation.

The amount of shares involved

A single-minded focus on the number of shares is inconsistent with CDI 612.09 and the facts and circumstances recited above.

We understand that several years ago the Staff became increasingly concerned about public resales of securities purchased in “toxic” transactions. The Staff believed that public investors often did not have an appropriate understanding as to the nature of the investment being made or the negative impact that such transactions could have on the market prices of the shares involved. In many of these “toxic” transactions, an issuer would commit to issuing shares at a conversion price that floated in accordance with the market price of the underlying common stock. When the deals were announced, the stock prices typically fell with the result that the issuer ended up issuing significant blocks of stock -- in many cases well in excess of 100% of the shares previously outstanding. In these toxic situations, existing investors or investors who purchased shares after the announcement of the transaction frequently faced unrelenting downward pressure on the value of their investments. In too many of these cases, the shares held by non-participants in these transactions were ultimately rendered worthless.

In order to combat the effects of these toxic transactions, the Office of Chief Counsel and the senior Staff members of the Commission’s Division of Corporation Finance began to look at ways to discourage toxic transactions and to limit the impact of these transactions. One way to do so was to limit the ability of the investors in those transactions to have their shares registered.

We understand that, in order to monitor these types of transactions, the Staff compared the number of shares an issuer sought to register with the number of shares outstanding and held by non-affiliates as disclosed in the issuer’s Annual Report on Form 10-K. As we understand it, the Staff was instructed to look more closely at any situation where an offering involved more than approximately one-third of the public float. If an issuer sought to register more than one-third of its public float, the Staff was instructed to examine the transaction to see if it implicated Staff concerns that a secondary offering might be a “disguised” primary offering for Rule 415 purposes. According to the Office of Chief Counsel, the test was intended to be a mere screening test and was not intended to substitute for a complete analysis of the factors cited in CDI 612.09. As far as we are aware, no rationale for the one-third threshold has ever been articulated by the Staff, other than that it is an easy criteria to apply. We understand that the Staff’s focus shifted in late 2006 to “Extreme Convertible” transactions to avoid disrupting legitimate PIPE transactions1. As described above, the terms of the 2012 Financing do not implicate any of the concerns leading to the focus on “extreme convertible” situations.

The availability of Rule 415 depends on whether the offering is in fact made by selling stockholders or deemed to be made by or on behalf of the issuer. In order for the Staff to determine that the offering is really being made on behalf of the issuer, by definition, the Staff must conclude that the selling stockholders are seeking to effect a distribution of the shares. However, if the Staff’s concern is that a distribution is taking place, the number of shares being registered should be one of the less important factors in the Staff’s analysis. There are too many other factors that need to be considered.

Focusing solely on the number of shares being registered in relation to the shares outstanding or the public float has a disproportionate impact on smaller public companies -- exactly those issuers who have very limited options to raise funds. A focus on sheer numbers also ignores a fundamental aspect of these transactions: investors in PIPEs are funding business plans and strategic initiatives, not looking to take control of public issuers or to engage in inappropriate distributions of stock. In this case, the selling stockholders who purchased shares of Former ADMA’s common stock in the 2012 Financing evaluated an investment in the Company on the basis of the business purpose for the offering and whether they believed the Company’s proposed use of proceeds was rational and likely to produce above average investment returns. The number of Registrable Shares they may end up owning is just a mathematical result of the size of the investment, the price per share and the Company’s market capitalization. PIPE investors do not typically look to acquire a specific proportion of a company and then calculate an investment amount based on a desired level of ownership. A focus on the percentage of the public float or the percentage of the shares outstanding, would unfairly penalize smaller companies without apparent justification.

___________________

1 See Speech by John W. White; Keller and Hicks: Unblocking Clogged PIPEs.

CDI 612.12 with respect to the Securities Act rules describes a scenario where a holder of well over one-third of the outstanding stock is able to effect a valid secondary offering. The interpretation states, in relevant part, that:

A controlling person of an issuer owns a 73% block. That person will sell the block in a registered “at-the-market” equity offering. Rule 415(a)(4) applies only to offerings by or on behalf of the registrant. A secondary offering by a control person that is not deemed to be by or on behalf of the registrant is not restricted by Rule 415(a)(4).

This interpretive position suggests that the holder of well in excess of one-third of the public float may effect a valid secondary offering of its shares unless other facts -- beyond the mere level of ownership -- indicate that the affiliate is acting as a conduit for the issuer.

Furthermore, the dollar value of the shares registered in relation to the proceeds that the Company received from the selling stockholders for the securities, excluding amounts of proceeds that were returned (or will be returned) to the selling stockholders and/or their affiliates in fees or other payments, does not indicate the existence of an underwriting relationship between the Company and the selling stockholders.

In the 2012 Financing, the Company received $17,287,289 in cash and cancelled $262,740 in aggregate principal amount and accrued interest with respect to certain notes held by selling stockholders for total gross proceeds of $17,550,029. The registration statement covers the resale of 1,969,026 shares of common stock. Of that amount, 1,828,128 Registrable Shares were issued in the reverse merger in exchange for shares sold to selling stockholders in the 2012 Financing at a price of $9.60 per share for total gross proceeds of $17,550,029. The dollar value of the securities acquired by selling stockholders in the 2012 Financing is therefore the same as the gross proceeds received by the Company from the sale of the shares exchanged in the reverse merger for Registrable Shares and the cancellation of such notes. The Placement Agent Warrants, by their terms, become exercisable on August 11, 2012. Based on the exercise price, the Company could receive additional proceeds of up to $843,504 if all of the Placement Agent Warrants are fully exercised, which is equivalent to $9.60 per share, the price per share at which common stock of Former ADMA was sold to the selling stockholders in the 2012 Financing.

The Securities Purchase Agreement and the Registration Rights Agreement in the 2012 Financing obligate the Company to make payments to the selling stockholders in certain circumstances, such as late charges, payments upon an event of default, and charges relating to blackout periods or the failure of the Company to file, have declared or maintain effective, the registration statement within certain time periods. However, the Company does not contemplate currently that it will have an obligation to make any of such payments. As such, these payments should not be deemed to be amounts of proceeds that will be returned to the selling stockholders and/or their affiliates in fees or other payments. The terms of the Securities Purchase Agreement in connection with the 2012 Financing do not have any “synthetic discounts” or “equity conditions” that would compel the Company to return proceeds upon adverse trading events that are present in certain PIPEs the Staff might view as abusive.

Since the gross proceeds received by the Company in the 2012 Financing are equal to the value of the 1,828,128 Registrable Shares issued in exchange for the shares sold in the 2012 Financing, the selling stockholders did not purchase such Registrable Shares at any “discount.” Neither will the placement agent in the 2012 Financing purchase the shares underlying the Placement Agent Warrants at a discount.

To the extent that any amount of shares is relevant to the determination of whether an offering styled as a secondary one is really a primary offering, it should, in our case, be the number of Registrable Shares issued to those persons and entities that were Affiliates of the Company prior to the 2012 Financing. As stated above, only 572,918 Registrable Shares are held by persons or entities that were Affiliates of the Company prior to such financing, those being the Grossman Group and Aisling and its control person Steven Elms. That number represents merely 19% of the total number of shares of common stock of the Company outstanding.

Conclusion: Considering all circumstances, the selling stockholders are not acting as a conduit for the Company

Considering the factors listed in CDI 612.09, (i) the selling stockholders made fundamental decisions to invest in the Company, (ii) the selling stockholders have represented their investment intent and disclaimed any intent to distribute their Registrable Shares in violation of any securities laws; the Registrable Securities include no shares issuable upon conversion of notes that would contain toxic or other abusive provisions that have in the past merited special concerns by the Staff, (iii) the selling stockholders are individuals and private investment funds that buy and sell portfolio securities for their own accounts, and (iv) as all of the facts and analysis provided above demonstrate, the selling stockholders are not engaging in a distribution and are not acting as conduits for the Company. There is no evidence to suggest that any of the selling stockholders are acting in concert to effect a coordinated distribution of the Registrable Shares. In addition, the selling stockholders beneficially own so much common stock that it would be virtually impossible for them to distribute immediately all of the Registrable Shares because there is no active trading market for the Company’s common stock. The number of Registrable Shares is reasonable in relation to other transactions that have been reviewed and cleared by the Staff. None of the selling stockholders are in the business of underwriting securities. In these circumstances we are of the view that the offering the Company seeks to register is a valid secondary offering and may proceed consistent with Rule 415.

Read in the reply
Outside Cover Page of Prospectus
SEC asked (5)
We note on page 39 and elsewhere that your common stock is not traded on any national securities exchange but that you will seek to have the common stock quoted on the OTCBB. Notwithstanding our comment 4 above, please revise here to state that the selling stockholders will sell their shares at a fixed price per share until your shares are quoted on the OTCBB and thereafter at prevailing market prices or privately
Rest of the question

negotiated prices.

ADMA answered
The Company has added the requested disclosure to the prospectus cover.
Read in the reply
Signatures
SEC asked (6)
Please revise so that the second half of the signature block is signed by persons with the indicated capacity of principal financial officer and either principal accounting officer or controller.
ADMA answered
The Company has made the requested revision to the Amendment.
Read in the reply
Exhibit 5.1
SEC asked (7)
Please delete the second sentence in the first full paragraph on page 2. Such a limitation on the scope of documents examined is not appropriate. In addition this appears inconsistent with the first sentence on page 2.
ADMA answered
Exhibit 5.1 has been revised to reflect the Staff’s request and a revised Exhibit 5.1 has been refiled with the Amendment.
Read in the reply
General
SEC asked (1)
We note your response to our prior comment 1. Please refer to the first paragraph of the risk factor beginning “We are an „emerging growth company‟” on page 32. Please revise the reference to the “transitional period” in this paragraph to explain that this means that the reduced disclosure requirements discussed will be available as long as you are an emerging growth company.
ADMA answered
The Company has made the requested revision on page 32 of the Amendment.
Read in the reply
General
SEC asked (2)
We note your response to our prior comment 4. We note the statement in your response that all of the selling stockholders represented to the company that they were not acquiring their securities with a view to distribution or resale of the securities “except in full compliance with all applicable provisions of the Securities Act.” Please tell us whether any of the selling stockholders acquired their securities with
Rest of the question

a view to distribution, even if they intended to comply with the Securities Act.

ADMA answered
By virtue of conversations between representatives of the Company and the selling stockholders, the Company understands that none of the selling stockholders acquired their securities with a view to distribution of the securities, but rather acquired them for investment.
Read in the reply
Outside Cover Page of Prospectus
SEC asked (3)
We note your response to our prior comment 5. Please revise to name a fixed price per share at which the selling stockholders will sell their shares until your shares are quoted on the OTCBB.
ADMA answered
The Company has added the requested disclosure on the outside cover page of the prospectus as well as on page 77 of the Amendment. The fixed price per share of $9.60 is based on the price per share in the 2012 Financing.
Read in the reply
Risks Relating to Our Securities, page 30
SEC asked (4)
Refer to your disclosure that you are an “emerging growth company” on page 32. Please expand the second paragraph under this heading to also provide a cross reference to the Critical Accounting Policies section of Management‟s Discussion and Analysis for a further discussion of the extended transition period for complying with new or revised accounting standards.
ADMA answered
The Company has added the requested disclosure on page 32 of the Amendment.
Read in the reply
Critical Accounting Policies and Estimates, page 61
SEC asked (5)
Please expand your disclosures to more fully describe the implications of the extended transition period provided by the JOBS Act. Specifically, please clarify that you may take advantage of the extended transition period provided in Securities Act Section 7(a) (2)(B) until the first to occur of the date you (i) are no longer an “emerging growth company” or (ii) affirmatively and irrevocably opt out of the extended
Rest of the question

transition period provided in Securities Act Section 7(a)(2)(B). Accordingly, until the date you are no longer an “emerging growth company” or affirmatively and irrevocably opt out of the exemption provided by Securities Act Section 7(a)(2)(b), upon issuance of a new or revised accounting standard that applies to your financial statements and has a different effective date for public and private companies, you will disclose the date on which adoption is required for non-emerging growth companies and the date on which you will adopt the recently issued accounting standard.

ADMA answered
The Company has added the requested disclosure on page 65 of the Amendment.
Read in the reply
Outside Cover Page of Prospectus
SEC asked (1)
We note your response to our prior comment 3. We note on page 75 that you issued shares in the 2012 Financing at $9.60 per share to Burrill, Aisling, and the Grossman Group and that these selling shareholders are initially offering your securities at $9.60 per share. Please explain how $9.60 per share constitutes a bona fide estimate of the maximum price per share.
Rest of the question

Your explanation should address the fact, as appropriate, that the $9.60 per share price was the original price paid by certain of the selling shareholders and that this prohibits them from making any profit on sales unless and until there is an active trading market. This particular fact suggests that $9.60 per share is not a bona fide estimate of the maximum offering price. Alternatively, increase the fixed price to a bona fide estimate and pay any additional filing fee.

ADMA answered
As discussed with Mr. Brown, the Company has revised its disclosure to indicate that until such time as its shares are quoted on the OTCBB, the selling stockholders will sell the shares covered by the prospectus at a range of $9.60 to $11.50 per share. The Company has paid an additional filing fee with respect to the difference between $11.50 and $9.60 per share.

The Company believes that the range of $9.60 to $11.50 establishes a reasonable bona fide estimate of a valid range for a sales price of the shares covered by the prospectus at times prior to quotation of the shares on the OTCBB.
Rest of the answer

First, with respect to the low end of the range, the Company believes that $9.60 represents an arms-length, independent stock price valuation between the investors, the Company and the Company’s financial advisors Rodman & Renshaw and is a reasonable estimate of the low end of the range as it represents a break-even point for the selling stockholders. To the extent that the Company believes that the period of time between the effective date of the registration statement and the date the shares are quoted on the OTCBB will be very limited, were issues to arise for a selling stockholder, that the Company cannot predict, selling stockholders could seek to recover their investment. In that regard, the Company believes that selling stockholders would expect to receive a sales price equal to no less than their purchase price of $9.60 per share.

With regard to the high end of the range, the Company again looks to the short period of time that is anticipated between the effective date of this registration statement and the date that the shares are listed on the OTCBB. The Company cannot predict whether any events might occur during such short period of time that would trigger dramatic increases in the price per share of common stock. Accordingly, the Company believes that it is reasonable to expect that selling stockholders would seek an increase in valuation of no greater than approximately 20% per share, which would equal approximately $11.50.

The Company therefore believes that the range of $9.60 to $11.50 per share represents a bona fide estimate of an offering price by the selling stockholders during the period of time prior to the shares being quoted on the OTCBB.

Read in the reply
Determination of Offering Price, page 39
SEC asked (2)
We note your response to our prior comment 3. Please revise your disclosure here to be consistent with your disclosure on the outside cover page of the prospectus indicating that until your shares are quoted on the OTCBB, the selling stockholders will sell the shares covered by this prospectus at a fixed price.
ADMA answered
As discussed with Mr. Brown, the Company has revised its disclosure to indicate that until such time as its shares are quoted on the OTCBB, the selling stockholders will sell the shares covered by the prospectus at a range of $9.60 to $11.50 per share.
Read in the reply

Form 8-K

2012-03-09 to 2012-07-09 · 44 questions · 3 letters from the SEC, 7 from the company
Review closed 2012-07-09
RevenueInventoryRisk factorsLiquidity and cashResults discussion (MD&A)Legal and contingenciesSegmentsGoodwill and impairment
Safe Harbor Statement Under the Private Securities Litigation Reform Act, page 2
SEC asked (1)
Please remove reference to the safe harbors of the Private Securities Litigation Reform Act of 1995 including Section 27A of the Securities Act and Section 21E of the Exchange Act given that you appear to be a penny stock issuer, or tell us why this is not necessary. Please refer to Section 27A(b)(1)(C) of the Securities Act and 21E(b)(1)(C) of the Exchange Act.
ADMA answered
The Company has revised the disclosure on page 2 of the Amendment to eliminate the reference to the safe harbors of the Private Securities Litigation Reform Act of 1995.
Read in the reply
Business of ADMA, page 10 · General
SEC asked (2)
Please revise to define industry specific terms when first used, such as “immune globulins,” “polyclonal,” and “RSV,” on page 10 and “PIDD” on page 11.
ADMA answered
The Company has revised the disclosure on page 12 of the Amendment to define industry specific terms upon first use.
Read in the reply
Overview, page 10
SEC asked (3)
Please balance the disclosure in the second paragraph to clarify, as indicated on page 21, that the results of your Phase II clinical trials may not be indicative of future results.
ADMA answered
The Company has revised the disclosure on page 12 of the Amendment in response to the Staff’s comment.
Read in the reply
Overview, page 10
SEC asked (4)
We note the statement in the second paragraph that ADMA is preparing to conduct a Phase III clinical trial “in order to gain FDA approval” of RI-001. Please revise to state that the FDA may require additional Phase III trials and Phase IV trials after this planned Phase III trial. Additionally please revise to clarify that it is possible that the FDA may not grant approval.
ADMA answered
The Company has revised the disclosure on page 12 of the Amendment in response to the Staff’s comment.
Read in the reply
Overview, page 10
SEC asked (5)
Please revise to discuss how you have developed RI-001. Explain whether you developed it internally or acquired it from another party.
ADMA answered
The Company has revised the disclosure on page 12 of the Amendment in response to the Staff’s comment.
Read in the reply
Background of the Plasma Industry, page 11
SEC asked (6)
Please refer to the second paragraph on page 11. Please refrain from referring to compound growth rates here and elsewhere as these represent two discrete snapshots in time but do not show trends or events during the remaining period.
Rest of the question

Otherwise, please revise to disclose the information in a manner that conveys the interim trends or events and presents a more complete picture of the worldwide revenue growth within the industry.

ADMA answered
The Company has revised the disclosure on page 13 of the Amendment to eliminate the reference to compound growth rates.
Read in the reply
Background of the Plasma Industry, page 11
SEC asked (7)
Please refer the second paragraph on page 11 regarding the $11.8 billion worldwide market and $4.5 billion United States market for the plasma industry, the third paragraph on page 11 regarding the $5.1 billion worldwide IGIV market, and the fourth paragraph on page 11 regarding the $900 million worldwide hyperimmune products market.
Rest of the question

Please revise to state, if true, that RI-001, if approved for treatment of PIDD by the FDA, would represent only a sub-segment of each of these markets. Additionally please balance references to worldwide markets by stating that you currently only have plans for gaining regulatory acceptance in the United States.

ADMA answered
The Company has revised the disclosure on page 14 of the Amendment by eliminating the references described in the Staff’s comment and has added disclosure to the risk factor on page 28 that it currently only has plans for gaining regulatory approval in the United States.
Read in the reply
Our Strategy, page 11
SEC asked (8)
For each business initiative you list, please revise to provide a timeline including milestones and the costs you will face at each step along the way. Discuss what steps you have taken so far. Explain when you expect each initiative to generate revenue. Additionally, please explain which initiatives will require you to raise additional capital.
ADMA answered
The Company has revised the disclosure on pages 14-15 of the Amendment in response to the Staff’s comment.
Read in the reply
Our Strategy, page 11
SEC asked (9)
Please revise to address your strategy in the event the FDA requires additional Phase III trials or Phase IV trials. Discuss a timeline including costs and whether additional capital would be needed.
ADMA answered
The Company has revised the disclosure on page 12 of the Amendment in response to the Staff’s comment. Since the Company’s strategy in the scenario described in the Staff’s comment would depend on the specific requirements imposed by the FDA, and since a timeline and corresponding costs are difficult to predict, the Company has added language on page 12 highlighting the risk of additional Phase III trials or Phase IV trials.
Read in the reply
Our Strategy, page 11
SEC asked (10)
You state here that ADMA BioCenters received its FDA license in August 2011. We also note on page F-6 of Exhibit 99.2 that you founded ADMA BioCenters Georgia, Inc. on April 3, 2008. Please tell us, with a view towards revised disclosure, what operations were conducted by the facility prior to receiving the FDA license and when the facility began collecting plasma.
ADMA answered
The Company has revised the disclosure on page 15 of the Amendment to clarify that prior to receiving its FDA license, the work at the Georgia facility consisted of obtaining local approvals, undergoing federal and state inspections, validating plasma collection systems, implementing quality programs for plasma collection, entering into vendor agreements, training and hiring staff and responding to FDA request letters.
Rest of the answer

Further, the Company began to collect plasma in February 2009, as the FDA required a minimum of three months of fully documented quality assurance records to be completed prior to a submission for FDA licensure.

Read in the reply
Our Product Candidate, page 12
SEC asked (11)
Please tell us, with a view towards revised disclosure, why you believe RI-001 will be clearly differentiated from currently marketed IGIV products.
ADMA answered
The Company has revised the disclosure on page 16 of the Amendment in response to the Staff’s comment to clarify that RI-001 will be differentiated from currently marketed IGIV products because of the Company’s proprietary methods of selecting and screening plasma donors and the manufacturing processes it intends to employ.
Read in the reply
Manufacturing and Supply, page 13
SEC asked (12)
We note that you have filed the manufacturing and supply agreements with Biotest Pharmaceuticals Corporation as material contracts. Please revise this section to disclose the material terms of these agreements. Please also disclose more specifically to what extent you intend to rely on third parties for blood plasma sourcing.
ADMA answered
The Company has revised the disclosure on page 18 of the Amendment in response to the Staff’s comments.
Read in the reply
Manufacturing and Supply, page 13
SEC asked (13)
Please disclose the precautions your manufacturer is required to take to protect your trade secrets.
ADMA answered
The Company has revised the disclosure on page 18 of the Amendment in response to the Staff’s comment.
Read in the reply
Intellectual Property, page 14
SEC asked (14)
Please revise to state, as indicated on page 22, that you do not own any issued patents and do not have any patent applications in process.
ADMA answered
The Company has revised the disclosure on page 19 of the Amendment in response to the Staff’s comment.
Read in the reply
Government Regulation and Product Approval, page 14
SEC asked (15)
Please revise to address the regulation and licensing of ADMA BioCenters.
ADMA answered
The Company has revised the disclosure on page 20 of the Amendment in response to the Staff’s comment.
Read in the reply
Risk Factors, page 18
SEC asked (16)
We note the reference to known “and unknown” risks and the statement that “[t]he risks described below are not the only ones the Company will face.” All material risks should be discussed in this section. If risks are not deemed material they should not be mentioned. Please revise accordingly.
ADMA answered
The Company respectfully submits that the Risk Factors in the Amendment disclose all material risks known to be faced by the Company and has revised the preamble to the Risk Factors on page 25 accordingly.
Read in the reply
Risk Factors, page 18
SEC asked (17)
Please revise to include a risk factor discussing, if true, that your Chief Executive Officer has no experience managing a public company.
ADMA answered
The Company has revised the disclosure on page 33 of the Amendment to add the requested risk factor.
Read in the reply
To date, we have generated limited product revenues, page 18
SEC asked (18)
Please revise to state, as indicated on page 34, that you estimate you will run out of funds after the third quarter of 2013, but may run out sooner and require additional capital sooner.
ADMA answered
The Company has revised the disclosure on page 25 of the Amendment in response to the Staff’s comment.
Read in the reply
We do not own any issued patents, page 22
SEC asked (19)
Please provide a separate risk factor addressing risks that third parties may obtain patents and that you would then be infringing on those patents unless you negotiate appropriate licenses.
ADMA answered
The Company has revised the disclosure on page 32 of the Amendment to add the appropriate risk factor.
Read in the reply
Management’s Discussion and Analysis or Plan of Operation, page 31 · Results of Operations, page 31
SEC asked (20)
Please consider including a tabular presentation of period to period comparative data for clarity in addition to your narrative discussion.
ADMA answered
The Company has revised the disclosure on page 45 of the Amendment to add the requested table.
Read in the reply
Liquidity and Capital Resources, page 34
SEC asked (21)
You state here that you expect your existing cash will be sufficient to fund your operations through the third quarter of 2013. You state on page 11, however, that you anticipate potential FDA approval of RI-001 by year-end 2014 and you intend to commercialize thereafter. Please address this potential funding shortfall more specifically, including your intended courses of action to remedy the deficiency.
ADMA answered
The Company has revised the disclosure on page 48 of the Amendment in response to the Staff’s comment.
Read in the reply
Liquidity and Capital Resources, page 34
SEC asked (22)
Please revise your discussion here to specifically state that the auditors’ report expressed substantial doubt as to your ability to continue as a going concern similar to the disclosure on page 18. Filings with such accountants’ reports must contain appropriate and prominent disclosure of financial difficulties and viable plans to overcome these difficulties.
Rest of the question

Refer to Section 607.02 of the Financial Reporting Codification for guidance.

ADMA answered
The Company respectfully submits that the auditor’s report accompanying the audited financial statements for the year ended December 31, 2011, which are being filed as exhibits to the Amendment, do not contain a “going concern” explanatory paragraph.
Read in the reply
Summary Compensation Table, page 39
SEC asked (23)
We note the statement on page 40 that Mr. Grossman received a bonus of $50,000 in connection with his 2011 performance. Please explain why you have not included this amount in the Summary Compensation Table as 2011 compensation.
ADMA answered
The Company has revised the disclosure on page 56 of the Amendment to include such bonus in response to the Staff’s comment.
Read in the reply
Certain Relationships and Related Transactions, and Director Independence, page 41
SEC asked (24)
Please revise to quantify the estimated amount of reimbursed legal fees, as discussed in the first paragraph.
ADMA answered
The Company has revised the disclosure on page 59 of the Amendment in response to the Staff’s comment.
Read in the reply
Certain Relationships and Related Transactions, and Director Independence, page 41
SEC asked (25)
Please disclose the number of shares underlying the common stock purchase warrants in the first paragraph under “Note Financings.”
ADMA answered
The Company has revised the disclosure on page 60 of the Amendment in response to the Staff’s comment.
Read in the reply
Other Related Party Transactions, page 42
SEC asked (26)
Please revise to identify the “affiliate of the Placement Agent.” Additionally please revise to identify the “bank of which Dr. Grossman serves as a director….”
ADMA answered
The Company has revised the disclosure on pages 60-61 of the Amendment to clarify that it is Rodman & Renshaw, LLC as Placement Agent, and not its affiliate, who will continue to hold an equity interest in the Company. The Company has also revised the disclosure to identify the bank as Pascack Bankcorp in response to the Staff’s comment.
Read in the reply
Description of Registrant’s Securities to be Registered, page 43
SEC asked (27)
You state that the summary of certain provisions of your capital stock is qualified by the “provisions of applicable law.” Such a qualification is inappropriate unless you file these provisions of applicable law as exhibits to the current report. Please revise accordingly.
ADMA answered
The Company has revised the disclosure on page 63 of the Amendment to eliminate such reference.
Read in the reply
Note 2 – Summary of Significant Accounting Policies · Inventory, page F-6
SEC asked (28)
We note your disclosure on page 31 of your Form 8-K that, during the nine months ended September 30, 2011, you incurred a loss on sale of research and development inventory of $1,934,630 because you disposed of your inventory of high priced, high titer plasma that you had previously acquired to conduct research and development for a second product that was subsequently abandoned.
Rest of the question

Please revise your disclosures in the Form 8-K and in this note to indicate the total amount of inventory sold at book value, proceeds received, and loss taken on sale.

ADMA answered
The Company has revised the disclosure on page F-6 of the Amendment in response to the Staff’s comment to disclose the total amount of inventory sold at book value ($2,439,487), proceeds received ($504,857) and loss recorded on the sales ($1,934,630).
Read in the reply
Note 2 – Summary of Significant Accounting Policies · Inventory, page F-6
SEC asked (29)
Further, we note your inventory policy indicates inventory is carried at the lower of cost or market. Given the significant loss on sale of plasma inventory taken during the nine months ended September 30, 2011, it appears the market value of remaining inventories may be significantly less than their carrying value. Please tell us how you have considered the remaining plasma inventory for impairment.
ADMA answered
The Company respectfully submits that the inventory sold during the nine months ended September 30, 2011 was older plasma with a relatively short remaining shelf life. This plasma was intended for use in the clinical trial manufacturing process. The delay in Phase III trials and the desire at the time to raise capital led to the sale of such plasma inventory. The sale was not in the ordinary course of business.

The Company's remaining inventory is more recently acquired and, therefore, has a longer remaining shelf life.
Rest of the answer

It is also critical for the manufacture of clinical trial drug to be used in the Phase III trial. Plasma with these specific titers is scarce and the replacement cost would be greater than the carrying value of the remaining plasma inventory. Due to these factors, no impairment charge was recorded on the remaining plasma inventory.

Read in the reply
Note 2 – Summary of Significant Accounting Policies · Inventory, page F-6
SEC asked (30)
As a related matter, we note your disclosure on page 10 of your Form 8-K that you own and operate ADMA BioCenters, an FDA-licensed source plasma collection facility that collects source plasma that may be manufactured into finished goods by third-party manufacturers or sold in the open market.
Rest of the question

Please tell us why you have not recorded the sale of the plasma inventory as revenue and the related cost of such plasma as cost of sales within operations on your Condensed Consolidated Statements of Operations on page F-3. Include in your response whether ADMA BioCenters has sold plasma to third party manufacturers or in the open market for any period presented.

ADMA answered
The Company respectfully submits that the plasma inventory sold during the nine months ended September 30, 2011 was purchased from third parties specifically for use in research and development activities. It was not collected at the Company’s collection facility and sold in the ordinary course of business. Therefore, the sale was not recorded as revenue with related cost of sales in the Company’s condensed consolidated statements of operations.

Plasma collected from the Company’s plasma collection facility is ordinary source plasma without specific titers.
Rest of the answer

The FDA license for the plasma collection facility was received in 2011, and the first sale of plasma in the ordinary course of business did not occur until October 2011.

Read in the reply
Exhibit 10.10
SEC asked (31)
Please refile this material contract in its entirety, including Exhibit A.
ADMA answered
The Company has refiled Exhibit 10.10, including Exhibit A thereto.
Read in the reply
Our Strategy, page 14
SEC asked (1)
We note your response to our prior comment 8. Please revise the bulleted discussion “Develop and commercialize RI-001 as a treatment for PIDD” to state when you expect to generate revenue from the commercialization of RI-001 as a treatment for PIDD.
ADMA answered
The Company respectfully advises the Staff that it is unable to predict with reasonable certainty when it will generate revenues from the commercialization of RI-001. It has revised the disclosure on pages 15, 48 and F-7 of the Amendment to include such statement along with disclosure on the uncertainty surrounding the amount of additional financing required prior to revenue generation.
Read in the reply
Our Strategy, page 14
SEC asked (2)
Please revise the statement on page 15 that “ADMA plans to sell normal source plasma to buyers in the open market” to state, if true, that you are already selling normal source plasma. We note on page 45 that you recorded revenue during the most recently completed fiscal year “from the sale of blood plasma collected in [your] Georgia-based blood plasma collection center.”
ADMA answered
The Company has revised the disclosure on page 15 of the Amendment to provide the requested statement.
Read in the reply
Our Strategy, page 14
SEC asked (3)
Please revise the discussion on the bottom of page 15 to clarify whether additional FDA licensing, local approvals, and federal and state inspections will be required to open new ADMA BioCenters locations.
ADMA answered
The Company has revised the disclosure on page 15 of the Amendment to provide the requested statement.
Read in the reply
Our Product Candidate, page 16
SEC asked (4)
We note your response to our prior comment 11. We note the statement that you believe RI-001 will be clearly differentiated from currently marketed IGIV products in part because of “the manufacturing processes [the company] intends to employ.” We also note the statement on page 18 that “Biotest does not have access to [y]our trade secrets during the manufacturing of RI-001.” In light of this please revise to clarify
Rest of the question

how the manufacturing process will differentiate RI001. To the extent the manufacturing process to which you refer is Biotest’s rather than yours, please revise accordingly.

ADMA answered
The Company has revised the disclosure on page 16 of the Amendment to provide the requested clarification.
Read in the reply
Manufacturing and Supply, page 18
SEC asked (5)
Please refer to the second-to-last paragraph on page 18. Please revise to clarify what you are referring to by “ADMA’s contract laboratories.” Revise to clarify, if true, that this is not a reference to Biotest.
ADMA answered
The Company has revised the disclosure on page 18 of the Amendment to provide the requested clarification.
Read in the reply
Certain Relationships and Related Party Transactions, page 59
SEC asked (6)
Please revise to clarify the reference to “Item 404(c)(iii)” on page 61 as it is unclear to us to what you are referring.
ADMA answered
The Company has revised the disclosure on page 61 of the Amendment to provide the requested clarification.
Read in the reply
Exhibit 99.1 to Form 8-K/A filed March 29, 2012
SEC asked (7)
Refer to our previous comment 22. Please tell us how your auditor was able to come to the conclusion that a going concern paragraph was not necessary in their opinion issued on your December 31, 2011 audited financial statements.
Rest of the question

Specifically address, in expanded detail, your history of losses from operations, your cash flow burn rate, your disclosure on page F-7 that you have experienced net losses and negative cash flows from operations since inception and the fact that you expect these conditions to continue for the foreseeable future. In addition, address the fact that you will not be able to generate revenues from RI001 until after FDA approval which may not occur, and that you will need to secure additional funding prior to the third quarter of 2013 to continue development and operations.

ADMA answered
The Company respectfully advises the Staff that its private placement of securities in February 2012 provided the Company with approximately $15.2 million in net cash proceeds. As discussed in Note 1 (page F-7) to the Company’s 2011 consolidated financial statements, the Company expects such proceeds, along with its projected revenue, to provide sufficient cash flow to fund its operations through the third quarter of 2013.
Rest of the answer

Its cash used in operating activities was $4.8 million in 2010 and $1.4 million in 2011; accordingly, the Company believes that, based on historical cash flows and its projections, it will have adequate cash flow beyond one year from the date of the financial statements.

Read in the reply
Exhibit 99.1 to Form 8-K/A filed March 29, 2012
SEC asked (8)
In this regard, consideration should be given to including an explanatory paragraph that discloses the substantive reasons why the going-concern explanatory paragraph has been eliminated from the reissued report for December 31, 2010 by analogy to AU Section 508.69.
ADMA answered
The Company respectfully advises the Staff that in Note 1 to the Company’s 2011 consolidated financial statements, it discloses the following matters relating to its liquidity:

•

The Company has incurred net losses and negative cash flows from operations since inception - conditions that are expected to continue for the foreseeable future.

The Company has needed to raise capital to sustain operations.

The Company’s cash balances at December 31, 2011 were minimal.

In February 2012, the Company raised gross proceeds of $17.5 million in a private placement of securities (discussed in detail
Rest of the answer

in Note 12 (page F-20)).

The Company expects to be able to fund operations into the third quarter of 2013.

If estimates about revenues and expenses prove to be wrong, the Company may have to raise additional capital sooner than anticipated and no assurance can be given that additional financing will be available to the Company.

The Company believes that the disclosure in Note 1 to the consolidated financial statements is robust, clearly discloses the Company’s current financial position, and explains by reference to the proceeds from the private placement why the 2010 “going concern” explanatory paragraph was not repeated in the March 29, 2011 audit report. The Company respectfully advises the Staff that it does not believe it would be appropriate for management to disclose why it believes the auditors removed the “going concern” explanatory paragraph, as per your suggestion to analogize to AU Section 508.69.

Read in the reply
Inventories, page F-7, and · Revenue Recognition, page F-8
SEC asked (9)
Please revise both of these policies to distinguish between your treatment of the different types of plasma inventories you hold and sell as part of operations, and those you hold for use in research and development. Ensure consistency with your responses to our previous comments 29 and 30.
ADMA answered
The Company has added the requested disclosure to pages F-7 and F-8 of the Amendment.
Read in the reply
Inventories, page F-7, and · Revenue Recognition, page F-8
SEC asked (10)
As a related matter, please revise your discussion of research and development expenses on page 46 of the Form 8-K to specifically state, if true, that the plasma sold is not plasma collected at the Plasma center.
ADMA answered
The Company has added the requested disclosure to page 46 of the Amendment.
Read in the reply
General
SEC asked (1)
Please refer to comment 1 of our letter to you dated April 24, 2012 regarding your registration statement on Form S-1. Please make similar changes to this current report on Form 8-K. In addition, both here and in the Form S-1, consider describing the extent to which any of the emerging growth company exemptions are available to you as a smaller reporting company.
ADMA answered
The Company has added the requested disclosure to the Amendment.
Read in the reply
Manufacturing and Supply, page 18
SEC asked (2)
We note your response to our prior comment 5. As exhibits to your next amendment please file your agreements with contract laboratories that conduct and run your laboratory testing, including your proprietary assay, or explain to us why this is not required by Item 601(b)(10) of Regulation S-K.
ADMA answered
The Company respectfully advises the Staff that, with one exception, its business is not substantially dependent on any agreement it has in place with contract laboratories. The exception is an agreement for laboratory testing services, which agreement had not yet been entered into on February 13, 2012, the date on which the Form 8-K was originally filed. The Company expects to file this agreement as an exhibit to the next amendment to its registration statement on Form S-1 (File No. 333-180449).
Rest of the answer

The Company furthermore expects to file an Application for Confidential Treatment with respect to certain information contained in such agreement.

Read in the reply
Manufacturing and Supply, page 18
SEC asked (3)
Please revise to reconcile the statement in the first sentence of the last paragraph of this section that your “contract laboratories do not have access to [y]our trade secrets” with the third sentence in that paragraph stating that your “contract laboratories have informed [you] that they take all commercially reasonable steps to ensure the confidentiality of ADMA’s assay process, procedures, reagents, and other
Rest of the question

confidential information” and the statement in the first paragraph of this section that “ADMA relies on contract laboratories to conduct and run its laboratory testing, including its proprietary assay.” These statements statements appear to suggest that your contract laboratories may have access to your trade secrets such as your proprietary assay.

ADMA answered
The Company has revised the disclosure on page 18 of the Amendment to clarify that the contract laboratories do not have access to its trade secrets relating to donor selection and lot formulation during the manufacturing and testing of RI-001, that the contract laboratories do not assist with the determination of whether a donor is suitable for ADMA’s program and that the donor selection criteria and formulas employed with designing the manufacturing plasma pool are not shared with any third party, including the Company’s contract laboratories.
Read in the reply

Also in this review: company letter, Mar 23, 2012, company letter, May 23, 2012, company letter, Jun 4, 2012, company letter, Jun 15, 2012, closing letter, 2012-07-09

Letters without questions

Other letters

UPLOAD and CORRESP
10 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 45 letters filed since 2012-03-09. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.